Cellebrite DI (NASDAQ:CLBT) Stock Gets Price Target Bump from Needham & Company LLC

Cellebrite DI (NASDAQ:CLBT) had its price target lifted by investment analysts at Needham & Company LLC from $12.50 to $14.00 in a report issued on Thursday, Benzinga reports. The firm presently has a “buy” rating on the stock. Needham & Company LLC‘s target price points to a potential upside of 28.56% from the stock’s previous close.

CLBT has been the subject of a number of other reports. DA Davidson reissued a “buy” rating and set a $15.00 price target on shares of Cellebrite DI in a research note on Tuesday, September 15th. Lake Street Capital cut their price objective on Cellebrite DI from $21.00 to $15.00 and set a “buy” rating on the stock in a research report on Friday, August 14th. JPMorgan Chase & Co. reduced their target price on Cellebrite DI from $20.00 to $16.00 and set an “overweight” rating on the stock in a research note on Friday, August 14th. Finally, Weiss Ratings downgraded Cellebrite DI from a “sell (d+)” rating to a “sell (d)” rating in a research report on Thursday, August 27th. Four research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Cellebrite DI presently has a consensus rating of “Moderate Buy” and an average price target of $15.00.

Cellebrite DI Price Performance

Cellebrite DI stock opened at $10.89 on Thursday. The firm has a market capitalization of $2.72 billion, a P/E ratio of 49.50, a price-to-earnings-growth ratio of 1.95 and a beta of 1.06. Cellebrite DI has a 1-year low of $9.58 and a 1-year high of $19.98. The company’s 50-day moving average is $11.61 and its 200 day moving average is $13.24.

Cellebrite DI (NASDAQ:CLBT) last announced its earnings results on Thursday, November 12th. The company reported $0.17 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.09 by $0.08. The business had revenue of $149.02 million during the quarter, compared to analyst estimates of $145.83 million. Cellebrite DI had a return on equity of 15.58% and a net margin of 11.43%. Research analysts anticipate that Cellebrite DI will post 0.37 earnings per share for the current fiscal year.

Insider Transactions at Cellebrite DI

In related news, insider Thomas Hogan sold 25,299 shares of the stock in a transaction that occurred on Tuesday, August 25th. The stock was sold at an average price of $11.29, for a total value of $285,625.71. Following the transaction, the insider owned 765,249 shares of the company’s stock, valued at $8,639,661.21. This represents a 3.20% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CMO David Gee sold 4,323 shares of the firm’s stock in a transaction on Monday, August 24th. The stock was sold at an average price of $11.36, for a total value of $49,109.28. Following the transaction, the chief marketing officer owned 135,281 shares in the company, valued at $1,536,792.16. The trade was a 3.10% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 56,909 shares of company stock worth $641,890 in the last ninety days. 5.70% of the stock is owned by company insiders.

Hedge Funds Weigh In On Cellebrite DI

Several institutional investors have recently made changes to their positions in CLBT. Nine Ten Capital Management LLC raised its holdings in shares of Cellebrite DI by 19.8% in the second quarter. Nine Ten Capital Management LLC now owns 4,126,808 shares of the company’s stock valued at $60,251,000 after acquiring an additional 682,933 shares in the last quarter. Wellington Management Group LLP grew its holdings in Cellebrite DI by 93.7% during the 2nd quarter. Wellington Management Group LLP now owns 3,049,904 shares of the company’s stock worth $44,529,000 after acquiring an additional 1,475,579 shares in the last quarter. Renaissance Technologies LLC grew its holdings in Cellebrite DI by 14.7% during the 1st quarter. Renaissance Technologies LLC now owns 2,860,639 shares of the company’s stock worth $39,420,000 after acquiring an additional 365,700 shares in the last quarter. Principal Financial Group Inc. increased its position in Cellebrite DI by 33.9% during the 1st quarter. Principal Financial Group Inc. now owns 2,156,166 shares of the company’s stock valued at $29,712,000 after purchasing an additional 545,334 shares during the period. Finally, Weiss Asset Management LP increased its position in Cellebrite DI by 3,485.3% during the 1st quarter. Weiss Asset Management LP now owns 1,899,841 shares of the company’s stock valued at $26,180,000 after purchasing an additional 1,846,851 shares during the period. Hedge funds and other institutional investors own 45.88% of the company’s stock.

More Cellebrite DI News

Here’s some of the latest news about CLBT:

• Positive Sentiment: Q3 revenue was $149.0 million, above the $145.8 million analyst estimate, while EPS was $0.17. The company also reported 20% ARR growth, $26.7 million in net income, and a 31% trailing-twelve-month free-cash-flow margin. Cellebrite Reports Third-Quarter 2026 Results
• Neutral Sentiment: Full-year 2026 revenue guidance of $553 million to $558 million is broadly in line with the $556.8 million consensus estimate.
• Neutral Sentiment: Chief Revenue Officer Marcus Jewell sold 393 shares, a 0.09% reduction in his holdings; he retained 426,735 shares, making the sale relatively small. SEC filing

Cellebrite DI Company Profile

Cellebrite DI Ltd. develops digital intelligence software and services that help organizations access, collect, preserve and analyze digital evidence. Its tools are used to investigate information from mobile devices, computers, cloud sources and other digital systems. The company’s offerings include its UFED platform for extracting data from digital devices, Physical Analyzer for examining and interpreting evidence, and analytics and case-management tools such as Pathfinder and Guardian. Customers include law enforcement, public safety, intelligence and defense agencies, as well as organizations in the private sector.